MINNEAPOLIS, Minnesota – Cardiology device maker ATS Medical Inc. has received European regulatory clearance to sell an aortic valve that can be implanted without requiring sutures.
The company said its 3f Enable Aortic Bioprosthesis can be folded to allow placement through a small incision and then expanded once inside a patient. The device allows for less-invasive aortic valve replacement and shorter procedure times than other commercially available alternatives, according to a statement from ATS.
ATS’ stock price rose 5 percent Monday to close at $3.03.
ATS said the product’s release marks the first time a surgical aortic valve that is implanted “using a sutureless technique” has been cleared for commercial use.
ATS plans to release an updated version of the device late next year.
In September, ATS announced that Columbia University Medical Center achieved a milestone 100 implants of the 3f Aortic Bioprosthesis. ATS reported revenue of $18.8 million for the quarter ended Oct. 3, a 17 percent year-over-year increase. Operating loss narrowed to $0.6 million from $2.8 million in the third quarter of 2008.
Creating value with cheap medical devices (Best of MedCitizens)
Radiology group Radisphere pulls in $10M in equity
Is the early stage funding valley of death a myth?
Kidney failure treatment firm raising $1M; search for $5M continues
Sign up for MedCity News' e-newsletter, providing medical industry news from across the country.
Sign up
Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.
Amy SiegelHow low can you go? Creating value with cheap medical devices
Steven M. Auvil (Sponsored)5 things med tech companies need to know about the Leahy-Smith America Invents Act
Jim TateEscape Hatch for Electronic Submission of CQMs for Meaningful Use
Lisa Suennen2012 JP Morgan Healthcare’s (wo)men’s club is changing in a good way
Joe HageA huge American opportunity waiting to happen
Doug MowenMed tech consolidation brings a need for focus. Here are 2 ways to get it
Comments
Post a comment
[...] announced last week that it has received European regulatory clearance to sell its 3F Enable Aortic Bioprosthesis. The [...]
Comment by ATS Medical gets patent for laser-cutting technology used in heart procedures : MedCity News — December 15, 2009 @ 11:03 am
[...] said it expects sales to pick up in the second half of this year as it expands the rollout of its 3f Enable sutureless heart valve, which recently received European regulatory [...]
Comment by ATS Medical’s stock plummets on projections of fourth-quarter loss : MedCity News — January 12, 2010 @ 1:58 pm
[...] says the Enable, which received European regulatory clearance in December, is the first surgical aortic valve replacement approved for commercial use that is [...]
Comment by ATS Medical reports first commercial procedure using its sutureless aortic vavle : MedCity News — January 25, 2010 @ 10:46 am
Post a Comment